### Publication of Project Cost Limits Under Blanket Certificates

Order of the Director, OEP

February 5, 2008

Section 157.208(d) of the Commission's Regulations provides for project cost limits applicable to construction, acquisition, operation and miscellaneous rearrangement of facilities (Table I) authorized under the blanket certificate procedure (Order No. 234, 19 FERC ¶ 61,216). Section 157.215(a) specifies the calendar year dollar limit which may be expended on underground storage testing and development (Table II) authorized under the blanket certificate. Section 157.208(d) requires that the "limits specified in Tables I and II shall be adjusted each calendar year to reflect the 'GDP implicit price deflator' published by the Department of Commerce for the previous calendar year."

Pursuant to § 375.308(x)(1) of the Commission's Regulations, the authority for the publication of such cost limits, as adjusted for inflation, is delegated to the Director of the Office of Energy Projects. The cost limits for calendar year 2008, as published in Table I of § 157.208(d) and Table II of § 157.215(a), are hereby issued.

### List of Subjects in 18 CFR Part 157

Administrative practice and procedure, Natural gas, Reporting and recordkeeping requirements.

### J. Mark Robinson,

Director, Office of Energy Projects.

■ Accordingly, 18 CFR part 157 is amended as follows:

### PART 157—[AMENDED]

■ 1. The authority citation for part 157 continues to read as follows:

Authority: 15 U.S.C. 717-717w.

■ 2. Table I in § 157.208(d) is revised to read as follows:

§ 157.208 Construction, acquisition, operation, replacement, and miscellaneous rearrangement of facilities.

\* \* \* \* \* \* (d) \* \* \*

TABLE I

|      | Limit               |              |  |
|------|---------------------|--------------|--|
| Year | Auto. proj.<br>cost | Prior notice |  |
| 1982 | \$4,200,000         | \$12,000,000 |  |
| 1983 | 4,500,000           | 12,800,000   |  |
| 1984 | 4,700,000           | 13,300,000   |  |
| 1985 | 4,900,000           | 13,800,000   |  |

TABLE I—Continued

|      | Limit               |              |  |  |
|------|---------------------|--------------|--|--|
| Year | Auto. proj.<br>cost | Prior notice |  |  |
| 1986 | 5,100,000           | 14,300,000   |  |  |
| 1987 | 5,200,000           | 14,700,000   |  |  |
| 1988 | 5,400,000           | 15,100,000   |  |  |
| 1989 | 5,600,000           | 15,600,000   |  |  |
| 1990 | 5,800,000           | 16,000,000   |  |  |
| 1991 | 6,000,000           | 16,700,000   |  |  |
| 1992 | 6,200,000           | 17,300,000   |  |  |
| 1993 | 6,400,000           | 17,700,000   |  |  |
| 1994 | 6,600,000           | 18,100,000   |  |  |
| 1995 | 6,700,000           | 18,400,000   |  |  |
| 1996 | 6,900,000           | 18,800,000   |  |  |
| 1997 | 7,000,000           | 19,200,000   |  |  |
| 1998 | 7,100,000           | 19,600,000   |  |  |
| 1999 | 7,200,000           | 19,800,000   |  |  |
| 2000 | 7,300,000           | 20,200,000   |  |  |
| 2001 | 7,400,000           | 20,600,000   |  |  |
| 2002 | 7,500,000           | 21,000,000   |  |  |
| 2003 | 7,600,000           | 21,200,000   |  |  |
| 2004 | 7,800,000           | 21,600,000   |  |  |
| 2005 | 8,000,000           | 22,000,000   |  |  |
| 2006 | 9,600,000           | 27,400,000   |  |  |
| 2007 | 9,900,000           | 28,200,000   |  |  |
| 2008 | 10,200,000          | 29,000,000   |  |  |

■ 3. Table II in § 157.215(a) is revised to read as follows:

## § 157.215 Underground storage testing and development.

(a) \* \* \* (5) \* \* \*

TABLE II

| Year      | Limit       |  |  |
|-----------|-------------|--|--|
| 1982      | \$2,700,000 |  |  |
| 1983      | 2,900,000   |  |  |
| 1984      | 3,000,000   |  |  |
| 1985      | 3,100,000   |  |  |
| 1986      | 3,200,000   |  |  |
| 1987      | 3,300,000   |  |  |
| 1988      | 3,400,000   |  |  |
| 1989      | 3,500,000   |  |  |
| 1990      | 3,600,000   |  |  |
| 1991      | 3,800,000   |  |  |
| 1992      | 3,900,000   |  |  |
| 1993      | 4,000,000   |  |  |
| 1994      | 4,100,000   |  |  |
| 1995      | 4,200,000   |  |  |
| 1996      | 4,300,000   |  |  |
| 1997      | 4,400,000   |  |  |
| 1998      | 4,500,000   |  |  |
| 1999      | 4,550,000   |  |  |
| 2000      | 4,650,000   |  |  |
| 2001      | 4,750,000   |  |  |
| 2002      | 4,850,000   |  |  |
| 2003      | 4,900,000   |  |  |
| 2004      | 5,000,000   |  |  |
| 2005      | 5,100,000   |  |  |
| 2006      | 5,250,000   |  |  |
| 2007      | 5,400,000   |  |  |
| 2008      | 5,550,000   |  |  |
| * * * * * |             |  |  |

[FR Doc. E8–2531 Filed 2–12–08; 8:45 am]
BILLING CODE 6717–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### 21 CFR Parts 510 and 522

New Animal Drugs; Change of Sponsor: Ketamine

**AGENCY:** Food and Drug Administration,

HHS.

**ACTION:** Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for an abbreviated new animal drug application (ANADA) for ketamine hydrochloride injectable solution from Veterinary Research Associates, Inc., to Putney, Inc. DATES: This rule is effective February

**DATES:** This rule is effective February 13, 2008.

### FOR FURTHER INFORMATION CONTACT:

David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–276–8307, e-mail: david.newkirk@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Veterinary Research Associates, Inc., 2817 West Country Rd., 54G, Fort Collins, CO 80524, has informed FDA that it has transferred ownership of, and all rights and interest in, ANADA 200–073 for Ketamine Hydrochloride Injection, USP, to Putney, Inc., 400 Congress St., suite 200, Portland, ME 04101. Accordingly, the regulations are amended in 21 CFR 522.1222a to reflect this change of sponsorship.

Following these changes of sponsorship, Veterinary Research Associates, Inc., is no longer the sponsor of an approved application. In addition, Putney, Inc., is not currently listed in the animal drug regulations as a sponsor of an approved application.

Accordingly, 21 CFR 510.600(c) is being amended to remove the entries for Veterinary Research Associates, Inc.,

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

and to add entries for Putney, Inc.

### List of Subjects

### 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 522

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:

### **PART 510—NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In § 510.600, in the table in paragraph (c)(1) remove the entry for "Veterinary Research Associates, Inc." and alphabetically add a new entry for "Putney, Inc."; and in the table in paragraph (c)(2) remove the entry for "064408" and numerically add an entry for "026637" to read as follows:

## § 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

\* \* \* \* (c) \* \* \* (1) \* \* \*

| Firm   | Drug<br>labeler<br>code |   |   |   |  |
|--|-------------------------|---|---|---|--|
| *  | *                       | * | * | * |  |
| Putney, Inc., 400 Congress St., suite 200, Portland, ME 04101        |                         |   |   |   |  |
| *  | *                       | * | * | * |  |
| (2) * * *  |                         |   |   |   |  |
| Drug<br>labeler<br>code  | Firm name and address   |   |   |   |  |
| *  | *                       | * | * | * |  |
| 026637 Putney, Inc., 400 Congress St., suite 200, Portland, ME 04101 |                         |   |   |   |  |
| *  | *                       | * | * | * |  |

# PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 3. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

### § 522.1222a [Amended]

■ 4. In § 522.1222a, revise paragraph (b) by removing "064408" and numerically adding "026637".

Dated: January 31, 2008.

### Bernadette Dunham,

Director, Center for Veterinary Medicine. [FR Doc. E8–2607 Filed 2–12–08; 8:45 am] BILLING CODE 4160–01–8

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### **Food and Drug Administration**

### 21 CFR Part 520

## Oral Dosage Form New Animal Drugs; Phenylbutazone Tablets

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of two supplemental new animal drug applications (NADAs) filed by IVX Animal Health, Inc. The supplemental NADAs provide revised labeling for phenylbutazone tablets used in horses and dogs.

**DATES:** This rule is effective February 13, 2008.

#### FOR FURTHER INFORMATION CONTACT:

Melanie R. Berson, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240–276–8337, email: melanie.berson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: IVX Animal Health, Inc., 3915 South 48th Street Ter., St. Joseph, MO 64503, filed supplements to NADA 91–818 and NADA 94–170 for Phenylbutazone Tablets. The supplemental applications provide for revisions to warning statements on product labeling. The supplemental NADAs are approved as of January 17, 2008, and 21 CFR 520.1720a is amended to reflect the approval.

Approval of these supplemental NADAs did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.

The agency has determined under 21 CFR 25.33(a)(1) that these actions are of a type that do not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

### List of Subjects in 21 CFR Part 520

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to

the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

## PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

- lacksquare 1. The authority citation for 21 CFR part 520 continues to read as follows:
  - Authority: 21 U.S.C. 360b.
- $\blacksquare$  2. Revise § 520.1720a to read as follows:

### § 520.1720a Phenylbutazone tablets and boluses.

- (a) Specifications. Each tablet contains 100, 200, or 400 milligrams (mg), or 1 gram (g) phenylbutazone. Each bolus contains 2 or 4 g phenylbutazone.
- (b) *Sponsors*. See sponsor numbers in § 510.600(c) of this chapter, as follows:
- (1) No. 000061 for use of 100- or 400-mg or 1-g tablets, or 2- or 4-g boluses, in dogs and horses.
- (2) Nos. 000010 and 059130 for use of 100- or 200-mg or 1-g tablets in dogs and horses.
- (3) Nos. 000856, 058829, and 061623 for use of 100-mg or 1-g tablets in dogs and horses.
- (4) No. 055246 for use of 100-mg tablets in dogs.
- (5) No. 000143 for use of 1-g tablets in horses.
- (c) Conditions of use—(1) Dogs—(i) Amount. 20 mg per pound of body weight daily.
- (ii) *Indications for use*. For the relief of inflammatory conditions associated with the musculoskeletal system.
- (iii) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- (2) *Horses*—(i) *Amount.* 1 to 2 g per 500 pounds of body weight daily.
- (ii) *Indications for use*. For the relief of inflammatory conditions associated with the musculoskeletal system.
- (iii) Limitations. Do not use in horses intended for human consumption. Federal law prohibits the use of this drug in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: January 31, 2008.

### Bernadette Dunham,

Director, Center for Veterinary Medicine. [FR Doc. E8–2608 Filed 2–12–08; 8:45 am] BILLING CODE 4160–01–8